


Ask a doctor about a prescription for CLORAZEPATE NORMON 15 mg HARD CAPSULES
Package Leaflet: Information for the User
Clorazepate Normon 15 mg Hard Capsules EFG
Clorazepate Dipotassium
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
.
Contents of the pack and other information
Clorazepate Normon is a medicine that belongs to the group of tranquilizers, anxiolytics, derived from benzodiazepines.
It is indicated in all manifestations of anxiety that may occur in everyday psychological disorders and whose intensity does not reach a psychiatric dimension:
In general, anxiety or anguish, isolated or associated with depressive states.
Before taking this medicine, you must be sure that you will be able to sleep uninterrupted for 7-8 hours.
In case you get up at night, after taking a hypnotic (a medicine that induces sleep), a slow response to stimuli may appear, with the consequent risk of falls and dizziness.
Do not take Clorazepate Normon
Warnings and precautions
Consult your doctor or pharmacist before starting to take Clorazepate Normon.
The use of this type of medicine can lead to the development of physical and psychological dependence. The risk of dependence increases with the dose, the duration of treatment, the combination with alcohol or with certain medicines (anxiolytics, hypnotics, psychotropics), or if you have a history of dependencies (to medicines or other products).
In case of developing physical dependence, sudden interruption of treatment can produce withdrawal syndrome, which is manifested by headache or muscle pain, anxiety, muscle tension, restlessness, agitation, confusion, insomnia, and irritability. In severe cases, the following symptoms have been described: depersonalization, hyperacusis, tingling and cramps in the limbs, intolerance to light, sounds, and physical contact, tremors, hallucinations, or convulsions.
Consult your doctor or pharmacist if such symptoms appear. Your doctor will indicate the duration of your treatment (which should not exceed 4 to 12 weeks) and the precise way in which you should gradually reduce the dose until you stop treatment.
Some tolerance may develop after prolonged use of this medicine.
This medicine can induce anterograde amnesia, especially if used at bedtime and when sleep duration is short. To reduce this risk, you should ensure that you will be able to sleep uninterrupted for 7-8 hours.
When treatment is stopped, the symptoms that made it necessary may reappear (rebound insomnia and anxiety). This is a transient phenomenon that may be accompanied by mood changes, anxiety, restlessness, or sleep disorders. It is more likely to appear if treatment is stopped abruptly, so it should be gradually reduced.
Elderly people are more susceptible to adverse reactions such as drowsiness, dizziness, muscle weakness, which can cause falls and therefore serious injuries (see section “4. Possible side effects”). In these cases, a dose reduction is recommended.
Psychiatric and paradoxical reactions such as restlessness, agitation, irritability, aggression, delirium, fits of rage, nightmares, hallucinations, psychosis, inappropriate behavior, and other adverse effects on behavior may appear. In this case, you should consult your doctor about stopping treatment. These reactions are more frequent in children and elderly patients.
You should avoid using this medicine in combination with sodium oxybate, due to the risk of respiratory problems (respiratory depression).
Do not take Clorazepate Normon at the same time as opioids (medicines used to relieve severe pain, such as morphine or codeine) unless your doctor prescribes it, due to the possible risk of sedation, respiratory depression, coma, or even death (see “Use of Clorazepate Normon with other medicines”).
If you have suicidal tendencies and depression, you should use it with extreme caution. Consult your doctor before using this medicine, as it may unmask existing depression. Some studies have shown an increased risk of suicidal ideation, suicide attempt, and suicide in patients taking certain sedatives and hypnotics, including this medicine. However, it has not been established whether this is caused by the medicine or if there may be other reasons. If you have suicidal thoughts, contact your doctor as soon as possible for additional medical advice.
Also, consult your doctor if you have any of the following conditions:
Use of Clorazepate Normon with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
You should be especially careful with medicines that act on the central nervous system, as these medicines can increase central depression and this could have consequences on your ability to drive or use machines.
You should be especially careful if you are being treated with the following medicines:
The risk of developing a withdrawal syndrome increases when Clorazepate Normon is associated with benzodiazepines that have been prescribed as anxiolytics or hypnotics.
Use of Clorazepate Normon with food, drinks, and alcohol
Alcohol consumption should be avoided while taking this medicine. See section “Use of Clorazepate Normon with other medicines: alcohol”.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
There are limited data on the use of clorazepate dipotassium in pregnant women. Therefore, it is not recommended to use this medicine during pregnancy and in women of childbearing age who do not use contraceptives.
If you discover that you are pregnant or plan to have a baby, consult your doctor immediately to reassess the need for treatment.
If you take clorazepate dipotassium during the last three months of pregnancy or during childbirth at high doses, the newborn may experience drowsiness (sedation), respiratory problems (respiratory depression), muscle weakness (hypotonia), decreased body temperature (hypothermia), and difficulty feeding (problems with lactation causing low weight gain).
If you take it regularly at the end of pregnancy, your baby may experience withdrawal symptoms.
In this case, the newborn should be closely monitored during the postnatal period.
Breastfeeding
This medicine should not be taken during breastfeeding, as it passes into breast milk.
Driving and using machines
Clorazepate dipotassium can alter your ability to drive or operate machinery, as it can cause drowsiness, reduce your attention, or reduce your reaction ability. The appearance of these effects is more likely at the start of treatment or when the dose is increased. Do not drive or use machines if you experience any of these effects.
You should pay special attention to driving and using machines due to the risk of drowsiness, amnesia, altered concentration, and muscle function associated with the use of this medicine. The combination with other medicines can enhance the sedative effect.
Additionally, insufficient sleep periods can increase the deterioration of the state of alertness (see section “Use of Clorazepate Normon with other medicines”).
Follow exactly the administration instructions of Clorazepate Normon indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The duration of this treatment is limited. Your doctor will indicate the duration of your treatment with Clorazepate Normon. Do not stop treatment before, nor interrupt it abruptly, in order to avoid the possibility of appearance of a withdrawal syndrome or rebound insomnia (see “Warnings and precautions”).
The route of administration of Clorazepate Normon is oral.
Adults: The usual dose ranges from 5 to 30 mg of clorazepate dipotassium per day, which means
It can be administered in divided doses or in a single dose, preferably before bedtime.
The presentation that best suits the prescribed dose can be used (see “Other presentations”).
If you take more Clorazepate Normon than you should
Overdose is usually manifested by different degrees of central nervous system depression, ranging from drowsiness (feeling of sleep) to coma.
Deep sleep is the main sign of an overdose that can even become a coma, depending on the dose ingested.
In moderate cases, the symptoms include drowsiness, confusion, and lethargy; in more severe cases, ataxia (loss of coordination of movements), hypotonia, hypotension (decrease in blood pressure), respiratory depression, rarely coma, and very rarely death.
The prognosis is positive, the overdose does not represent a vital threat, at least in the absence of combination with other central depressants (psychotropic agents, alcohol), and as long as the subject is treated.
In case of overdose, the patient should be transferred to a specialized center and the usual precautions should be taken: induction of vomiting, gastric lavage, and monitoring of respiratory and cardiovascular parameters. If there is no improvement with stomach emptying, activated charcoal will be administered to reduce absorption.
Flumazenil can be used for the diagnosis and/or treatment of overdose as an antidote.
If you have taken more Clorazepate Normon than you should, consult your doctor, pharmacist, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Clorazepate Normon
Do not take a double dose to make up for forgotten doses.
If you stop taking Clorazepate Normon
Abrupt interruption of treatment can produce a withdrawal syndrome, which is manifested by headache or muscle pain, anxiety, muscle tension, restlessness, confusion, insomnia, and irritability (see section “Warnings and precautions”).
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Clorazepato Normon can cause adverse effects, although not all people suffer from them.
Adverse effects are presented grouped by organ and system classification and by frequency:
Very frequent: may affect more than 1 in 10 patients
Frequent: may affect up to 1 in 10 patients
Infrequent: may affect up to 1 in 100 patients
Rare: may affect up to 1 in 1,000 patients
Very rare: may affect up to 1 in 10,000 patients
Frequency not known: cannot be estimated from available data.
Adverse effects are related to the dose and individual patient sensitivity.
Immune System Disorders:
Psychiatric Disorders:
Infrequent: irritability, agitation, confusion.
Frequency not known: aggression, hallucination.
Nervous System Disorders:
Ocular Disorders:
Skin and Subcutaneous Tissue Disorders:
General Disorders and Administration Site Conditions:
Additionally, the following adverse effects have been reported with benzodiazepines: emotional bluntness, reduced alertness, headache, loss of movement coordination (ataxia), gastrointestinal disorders, changes in sexual appetite (changes in libido), and amnestic effects that may be associated with inappropriate behavior.
Psychiatric or paradoxical reactions with restlessness, delirium, rage, nightmares, psychosis, and inappropriate behavior, as well as other adverse effects on behavior.
Depression: the use of benzodiazepines may unmask pre-existing depression.
Dependence: administration of the product (even at therapeutic doses) may lead to the development of physical dependence: withdrawal of treatment may lead to the development of withdrawal or rebound phenomena (see "Warnings and Precautions" section). This occurs more rapidly with short-half-life benzodiazepines than with long-half-life benzodiazepines (several days).
Psychological dependence may occur. Cases of benzodiazepine abuse have been reported.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store below 25°C. Store in the original packaging to protect it from light and moisture.
Do not use Clorazepato Normon after the expiration date shown on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Clorazepato Normon
The active ingredient is potassium clorazepate. Each capsule contains 15 mg of potassium clorazepate.
The other components (excipients) are: potassium carbonate, talc, and calcium phosphate dibasic. The gelatin capsule is composed of: gelatin, titanium dioxide (E-171), erythrosine (E-127), and carmine indigo (E-132).
Appearance of the Product and Package Contents
Clorazepato Normon 15 mg hard capsules are presented in the form of pink/blue capsules.
Each package contains 20 capsules or 500 capsules (clinical package).
Marketing Authorization Holder and Manufacturer
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
OTHER PRESENTATIONS
Clorazepato Normon 5 mg hard capsules EFG
Clorazepato Normon 10 mg hard capsules EFG
Date of the Last Revision of this Prospectus:June 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es//
The average price of CLORAZEPATE NORMON 15 mg HARD CAPSULES in November, 2025 is around 1.47 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CLORAZEPATE NORMON 15 mg HARD CAPSULES – subject to medical assessment and local rules.